These results suggest that IBC should be preferably selected for younger patients, or those with brain metastasis, bone metastasis, and oligometastasis, and that PD‐L1 level is not an effective biomarker for IBC treatment. The gene discussed is CD274; the disease is inflammatory breast carcinoma.